유전자 편집 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 전달 방법별, 용도별, 모드별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Genome Editing Market Size, Share & Trends Analysis Report By Technology, By Delivery Method, By Application, By Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

유전자 편집 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 유전자 편집 시장 규모는 2030년에 250억 달러에 달할 것으로 예상되며, 2025-2030년에 걸쳐 16.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

유전자 편집 기술의 진보 증가, 유전체학 산업에 대한 자금 조달 및 투자 증가, 유전 질환의 유병률 증가, 치료 및 치료 개선의 필요성은 수익 성장을 가속하는 주요 요인입니다.

유전자 편집 기술의 진화는 시장의 수익 성장을 가속하는 또 다른 요인입니다. Genomics와 New England Biolab은 CRISPR 유전자 변형 도구 및 시약 개발 및 상업화를 위해 협력했습니다.

유전자 변형 도구의 치료 연구에 대한 응용이 진행됨에 따라 임상 검사에 들어가는 첨단 치료의 수가 증가하고 있습니다. 연구자들은 CRISPR과 같은 유전자 변형 장치가 다양한 만성 질환의 신속한 스크리닝 솔루션이 될 수 있는 가능성을 탐구하고 있습니다.

유전자 편집 시장 보고서 하이라이트

• 유전자 편집 기술 CRISPR은 생명 공학에서 급성장 기술이 될 것으로 예측됩니다.
• 유전자 편집 기술의 급속한 진보는 치료의 전망을 재구축해, 광범위한 유전성 질환, 혈액 질환, 대사성 질환, 감염성 질환의 치료를 목적으로 한 임상 검사의 급증을 촉진하고 있습니다.
• 생체 내 유전체 편집은 전 세계 치료 환경에서 혁신적인 힘으로 떠오르고 있습니다.전통적인 생체 외 방법과 달리, 생체 내 접근법은 환자의 몸 안에서 직접 유전자를 수정할 수 있게 하여 복잡한 세포 추출, 조작 및 재융합의 필요성을 없애줍니다.
• CRISPR/Cas9 부문은 2024년 세계 매출에서 44.36%의 최대 시장 점유율을 차지했습니다.
• 북미의 유전자 편집 시장은 유전자 편집 기술의 연구 개발에 대한 투자가 증가하고 있기 때문에 세계 시장을 독점하고, 2024년에는 44.59%의 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 유전자 편집 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련, 보조적인 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 유전자 편집 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 유전자 편집 시장 : 기술별, 추정 및 예측 분석

• 부문 대시보드
• 세계의 유전자 편집 시장의 기술 변동 분석
• 세계의 유전자 편집 시장 규모와 동향 분석(기술별, 2018-2030년)
• (크리스퍼)/Cas9
• TALEN/메가 TAL
• ZFN
• 메가뉴클레아제
• 기타

제5장 유전자 편집 시장 : 전달 방법 추정 및 예측 분석

• 부문 대시보드
• 세계의 유전자 편집 시장의 전달 방법 변동 분석
• 세계의 유전자 편집 시장 규모와 동향 분석(전달 방법별, 2018-2030년)
• 생체외
• 생체내

제6장 유전자 편집 시장 : 용도 추정 및 예측 분석

• 부문 대시보드
• 세계의 유전자 편집 시장의 용도 변동 분석
• 세계의 유전자 편집 시장 규모와 동향 분석(용도별, 2018-2030년)
• 유전자 공학
  • 세포주 공학
  • 동물유전공학
  • 식물성 기름전공학
  • 기타
• 임상용도
  • 진단 개발
  • 치료법의 개발

제7장 유전자 편집 시장 : 모드 추정 및 예측 분석

• 부문 대시보드
• 세계의 유전자 편집 시장의 모드 변동 분석
• 세계의 유전자 편집 시장 규모와 동향 분석(모드별, 2018-2030년)
• 계약
• 사내

제8장 유전자 편집 시장 : 최종 용도 추정 및 예측 분석

• 부문 대시보드
• 세계의 유전자 편집 시장의 최종 용도 변동 분석
• 세계의 유전자 편집 시장 규모와 동향 분석(최종 용도별, 2018-2030년)
• 생명공학과 제약회사
• 학술기관과 정부연구기관
• 계약 연구 기관

제9장 유전자 편집 시장 : 지역별, 추정 및 예측 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 기업/경쟁의 분류
• 전략 매핑
• 기업시장 포지셔닝 분석, 2024년
• 기업 프로파일/상장 기업
  • Merck KGaA
  • Takara Bio Inc.
  • Revvity, Inc.
  • Danaher Corporation
  • GenScript
  • New England Biolabs
  • Charles River Laboratories
  • Eurofins Scientific
  • Lonza
  • Thermo Fisher Scientific, Inc.

SHW

영문 목차

영문목차

Genome Editing Market Growth & Trends:

The global genome editing market size is expected to reach USD 25.00 billion in 2030 and is projected to grow at a CAGR of 16.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

Genome Editing Market Report Highlights:

• Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes.
• The rapid advancement of genome editing technologies is reshaping the therapeutic landscape, driving a surge in clinical trials aimed at treating a wide range of genetic, hematologic, metabolic, and infectious diseases.
• In vivo genome editing is emerging as a transformative force within the global therapeutic landscape. Unlike traditional ex vivo methods, in vivo approaches allow for direct gene modification inside the patient's body, eliminating the need for complex cell extraction, manipulation, and reinfusion.
• The CRISPR/Cas9 segment held the largest market share of 44.36% of the global revenue in 2024. This can be attributed to high precision & efficiency, high versatility & adaptability to different experimental designs, and cost-effectiveness with relatively low expense associated
• North America genome editing market dominated the global market and accounted for a 44.59% share in 2024, owing to the growing investments in the R&D of gene editing technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Delivery Method Segment
  • 1.2.3. Application Segment
  • 1.2.4. Mode Segment
  • 1.2.5. End-use Segment
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Genome Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Success in pre-clinical models drives demand for genome editing therapeutics
    • 3.2.1.2. Rising competition amongst market participants for business development
    • 3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
    • 3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
    • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.1.6. Rising adoption in agricultural biotechnology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges concerning clinical translation
    • 3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
    • 3.2.2.3. Off-target effects of CRISPR technology
• 3.3. Genome Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Genome Editing Market Technology Movement Analysis
• 4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. (CRISPR)/Cas9
  • 4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. TALENs/MegaTALs
  • 4.5.1. TALENs/MegaTALs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. ZFN
  • 4.6.1. ZFN market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Meganuclease
  • 4.7.1. Meganuclease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Genome Editing Market Delivery Method Movement Analysis
• 5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2018 to 2030 (USD Million)
• 5.4. Ex Vivo
  • 5.4.1. Ex vivo market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. In-Vivo
  • 5.5.1. In-vivo market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Genome Editing Market Application Movement Analysis
• 6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Genetic Engineering
  • 6.4.1. Genetic Engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Cell Line Engineering
    • 6.4.2.1. Cell line engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Animal Genetic Engineering
    • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Plant Genetic Engineering
    • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Applications
  • 6.5.1. Clinical applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Diagnostics Development
    • 6.5.2.1. Diagnostics development market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Therapy Development
    • 6.5.3.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Genome Editing Market Mode Movement Analysis
• 7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
• 7.4. Contract
  • 7.4.1. Contract market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Genome Editing Market: End-Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Genome Editing Market End-Use Movement Analysis
• 8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
• 8.4. Biotechnology and pharmaceutical companies
  • 8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Academic and government research institutes
  • 8.5.1. Academic and government research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Contract research organizations
  • 8.6.1. Contract research organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. U.S.
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Target disease prevalence
    • 9.4.1.4. Competitive scenario
    • 9.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Canada
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. Mexico
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. UK
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Target disease prevalence
    • 9.5.1.4. Competitive scenario
    • 9.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Germany
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. France
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. Spain
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Norway
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Target disease prevalence
    • 9.5.6.4. Competitive scenario
    • 9.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.7. Sweden
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Target disease prevalence
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Competitive scenario
    • 9.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.8. Denmark
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Target disease prevalence
    • 9.5.8.4. Competitive scenario
    • 9.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Japan
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Target disease prevalence
    • 9.6.1.4. Competitive scenario
    • 9.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Target disease prevalence
    • 9.6.2.4. Competitive scenario
    • 9.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. India
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Target disease prevalence
    • 9.6.5.4. Competitive scenario
    • 9.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Thailand
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Target disease prevalence
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. Competitive scenario
    • 9.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Brazil
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Target disease prevalence
    • 9.7.1.4. Competitive scenario
    • 9.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Argentina
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Target disease prevalence
    • 9.7.2.4. Competitive scenario
    • 9.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. South Africa
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Saudi Arabia
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Target disease prevalence
    • 9.8.2.4. Competitive scenario
    • 9.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. UAE
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Target disease prevalence
    • 9.8.3.4. Competitive scenario
    • 9.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.4. Kuwait
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Target disease prevalence
    • 9.8.4.4. Competitive scenario
    • 9.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Takara Bio Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Revvity, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Danaher Corporation
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. GenScript
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. New England Biolabs
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Charles River Laboratories
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Eurofins Scientific
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Lonza
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Thermo Fisher Scientific, Inc.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives

관련자료